SHP.L - Shire plc

LSE - LSE Delayed Price. Currency in GBp
4,508.00
-13.00 (-0.29%)
At close: 4:38PM BST
Stock chart is not supported by your current browser
Previous Close4,521.00
Open4,518.00
Bid3,900.00 x 51000
Ask4,610.00 x 53800
Day's Range4,500.50 - 4,538.00
52 Week Range2,940.50 - 4,662.00
Volume1,354,651
Avg. Volume2,455,829
Market Cap40.915B
Beta (3Y Monthly)1.19
PE Ratio (TTM)8.55
EPS (TTM)527.50
Earnings DateOct 25, 2018
Forward Dividend & Yield0.26 (0.58%)
Ex-Dividend Date2018-09-06
1y Target Est63.36
  • Reuters2 days ago

    Shire's drug for rare swelling disorder wins European panel green light

    A European Medicines Agency (EMA) panel on Friday recommended approving a potential blockbuster drug from Shire Plc to treat patients aged 12 and older with a rare hereditary disease that causes swelling in different parts of the body. The drug, Takhzyro, which Shire acquired through its $5.9 billion buyout of Dyax in 2016, is expected to generate about $2 billion in peak sales, analysts said. The recommendation by the EMA's Committee for Medicinal Products for Human Use (CHMP) will be a shot in the arm for Japan's Takeda Pharmaceutical Co Ltd, which is waiting for EU antitrust approval to wrap up its $62 billion acquisition of Shire.

  • GlobeNewswire2 days ago

    Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 days ago

    Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

    Dublin, Ireland – 19 October 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on rare diseases, announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of marketing authorisation of lanadelumab injection for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

  • GlobeNewswire2 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire2 days ago

    FDA Advisory Committee Recommends Approval of Shire’s Prucalopride (SHP555) for Chronic Idiopathic Constipation

    October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted unanimously (10 to 0) that the risk-benefit profile of prucalopride supports the approval of this New Drug Application (NDA). The FDA will take the advisory committee’s recommendation into consideration when the agency makes a final determination.

  • GlobeNewswire3 days ago

    Notice of Results

    Shire to announce third quarter 2018 results Dublin, Ireland – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce third quarter 2018 earnings on Thursday.

  • Reuters3 days ago

    Takeda gets Japanese approval for $62 billion Shire purchase

    "Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,”Takeda CEO Christophe Weber said in a statement. Takeda is also waiting for a nod from EU antitrust regulators.

  • Takeda gets Japanese approval for $62 billion Shire purchase
    Reuters3 days ago

    Takeda gets Japanese approval for $62 billion Shire purchase

    "Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,” Takeda CEO Christophe Weber said in a statement. Takeda is also waiting for a nod from EU antitrust regulators.

  • GlobeNewswire3 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire5 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Reuters5 days ago

    FTSE shrugs off Brexit impasse while Convatec and Superdry sink

    By Danilo Masoni and Helen Reid MILAN/LONDON (Reuters) - Britain's top share index managed a modest gain on Monday as a deadlock in Brexit talks depressed domestic stocks but helped multinational exporter ...

  • GlobeNewswire6 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Irish bioscience company opens new $1.2 billion Georgia plant
    American City Business Journals9 days ago

    Irish bioscience company opens new $1.2 billion Georgia plant

    Shire already employs about 900 people. But when it fully ramps up in Georgia, it’s expected to have about 1,500 workers between the manufacturing facility and its plasma collection centers.

  • GlobeNewswire9 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire10 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study
    Zacks10 days ago

    J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study

    J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.

  • GlobeNewswire11 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Moody's11 days ago

    Seven & i Holdings Co., Ltd. -- Moody's: Rated Japanese corporates' cash to stay high, but pace of growth to slow

    Moody's Japan K.K. says that the cash levels of rated Japanese non-financial companies will remain high through at least fiscal 2018 -- ending 31 March 2019 for most companies -- but that the pace of growth will slow as spending increases. "One indication of this trend is the fact that cash as a percentage of assets, which peaked at more than 9% in fiscal 2015, has since declined and will continue to do so through fiscal 2018," says Mihoko Manabe, a Moody's Associate Managing Director. "Looking ahead, we also expect that the rated companies' cash holdings, which totaled JPY33.7 trillion (USD306 billion) at the end of fiscal 2017, will rise 2% in fiscal 2018 and hold steady in fiscal 2019, a slowdown from growth of 5% in fiscal 2017," says Manabe.

  • GlobeNewswire13 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire16 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire17 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire18 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire19 days ago

    Director/PDMR Shareholding

    October 2, 2018– Shire plc. Notification of transactions by person discharging managerial responsibilities. Sarah Rixon Senior Company Secretarial Assistant.

  • GlobeNewswire19 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire20 days ago

    Form 8 (DD) - Olivier Bohuon

    FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)Rules 8.1, 8.2.